Search Results

Site Search

LinkedIn Login, Sign in | LinkedIn

Login to LinkedIn to keep in touch with people you know, share ideas, and build your career.

LinkedIn Login, Sign in | LinkedIn

Login to LinkedIn to keep in touch with people you know, share ideas, and build your career.

Assay finds genetic cause of low bile flow: Devin Oglesbee, Ph.D. - Insights

Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.

IDH assay facilitates timelier leukemia treatment: Rong He, M.D. - Insights

In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.

Key performance indicators for laboratory outreach programs - Insights

Key performance indicators (KPIs) should be a part of every laboratory’s quality improvement plan, and that includes outreach-specific KPI metrics. Financial, internal-facing, and client-facing KPIs for outreach programs help to create a...

Unique collaboration advances discoveries for rare disease - Insights

The nonprofit patient advocacy group called The MOG Project supports patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which is a rare and debilitating central nervous system demyelinating disorder. A...

Melanoma panel expands ability to diagnose tumors - Insights

Mayo Clinic Laboratories’ MayoComplete Melanoma Panel is a comprehensive test that better informs the prognosis and treatment of melanoma. It can be applied to unusual tumors that haven’t yet been identified as melanoma as well as melanomas...

Expanded colorectal cancer panel tests more genes - Insights

Mayo Clinic Laboratories has developed a new colorectal cancer test, the MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC), in response to the latest recommendations for testing and treatment from the American Society of Clinical...

Hepatocellular Carcinoma Risk Panel with GALAD Score - Insights

In this “Hot Topic,” Joshua Bornhorst, Ph.D., assistant professor of laboratory medicine and pathology at Mayo Clinic, reviews biomarker component testing for hepatocellular carcinoma, explains the GALAD score, and explores GALAD score...

Identifying disease biomarkers with phage immunoprecipitation sequencing - Insights

Mayo Clinic’s Advanced Diagnostics Laboratory researchers are using phage immunoprecipitation sequencing to discover new serological biomarkers for autoimmune diseases.